NASDAQ:MEDPMedpace Stock Price, Forecast & News

Medpace's stock was trading at $83.64 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MEDP stock has increased by 51.8% and is now trading at $126.95.
View which stocks have been most impacted by COVID-19.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Medpace.

Medpace is scheduled to release its next quarterly earnings announcement on Monday, October 26th 2020.
View our earnings forecast for Medpace.

Medpace Holdings Inc (NASDAQ:MEDP) posted its quarterly earnings data on Monday, July, 27th. The company reported $0.68 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.40 by $0.28. The firm earned $205 million during the quarter, compared to analyst estimates of $181.17 million. Medpace had a net margin of 12.11% and a return on equity of 16.05%. The business's revenue was down 4.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.81 EPS.
View Medpace's earnings history.

Medpace updated its FY20 earnings guidance on Monday, July, 27th. The company provided earnings per share (EPS) guidance of $3.62-3.83 for the period, compared to the Thomson Reuters consensus estimate of $2.33. The company issued revenue guidance of $880-920 million, compared to the consensus revenue estimate of $831.87 million.

5 brokers have issued 1-year price objectives for Medpace's shares. Their forecasts range from $75.00 to $124.00. On average, they expect Medpace's stock price to reach $97.67 in the next twelve months. This suggests that the stock has a possible downside of 23.1%.
View analysts' price targets for Medpace.

Media headlines about MEDP stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Medpace earned a coverage optimism score of -1.3 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
View the latest news about Medpace.

Medpace saw a decline in short interest in May. As of May 15th, there was short interest totaling 2,580,000 shares, a decline of 10.7% from the April 30th total of 2,890,000 shares. Based on an average trading volume of 387,100 shares, the short-interest ratio is currently 6.7 days. Currently, 9.8% of the shares of the company are short sold.
View Medpace's Short Interest.

Some companies that are related to Medpace include EXACT Sciences (EXAS), PPD (PPD), Charles River Laboratories Intl. (CRL), Icon (ICLR), Exelixis (EXEL), Syneos Health (SYNH), PRA Health Sciences (PRAH), BTG (BTGGF), National Research (NRC), Precigen (PGEN), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL), Luna Innovations (LUNA), Pieris Pharmaceuticals (PIRS) and Eloxx Pharmaceuticals (ELOX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), EXACT Sciences (EXAS), Baidu (BIDU), Advanced Micro Devices (AMD), Alibaba Group (BABA), Square (SQ), JD.Com (JD), Cisco Systems (CSCO), Intuitive Surgical (ISRG) and Trade Desk (TTD).

(MEDP) raised $150 million in an IPO on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Medpace's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (10.26%), Wasatch Advisors Inc. (7.23%), Pendal Group Ltd (3.04%), Boston Trust Walden Corp (1.11%), Fisher Asset Management LLC (1.01%) and Goldman Sachs Group Inc. (0.91%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Medpace Limited Partnership, Stephen P Ewald and Susan E Burwig.
View institutional ownership trends for Medpace.

MEDP stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Vanguard Group Inc., Federated Hermes Inc., MERIAN GLOBAL INVESTORS UK Ltd, WINTON GROUP Ltd, Glenmede Trust Co. NA, Russell Investments Group Ltd., and Goldman Sachs Group Inc.. Company insiders that have sold Medpace company stock in the last year include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Stephen P Ewald, and Susan E Burwig.
View insider buying and selling activity for Medpace.

MEDP stock was purchased by a variety of institutional investors in the last quarter, including Boston Trust Walden Corp, Wasatch Advisors Inc., Redwood Investments LLC, Nordea Investment Management AB, American Capital Management Inc., ClariVest Asset Management LLC, Raymond James & Associates, and Tudor Investment Corp Et Al.
View insider buying and selling activity for Medpace.

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MEDP stock can currently be purchased for approximately $126.95.

Medpace has a market capitalization of $4.50 billion and generates $860.97 million in revenue each year. The company earns $100.44 million in net income (profit) each year or $3.02 on an earnings per share basis. Medpace employs 3,500 workers across the globe.

The official website for Medpace is www.medpace.com.

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]